{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:30:35Z","timestamp":1793205035905,"version":"4.5.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41585-024-00885-9","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T08:01:50Z","timestamp":1716192110000},"page":"723-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Preclinical models of bladder cancer: BBN and beyond"],"prefix":"10.1038","volume":"21","author":[{"given":"David","family":"Matye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliann","family":"Leak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Woolbright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1780-3788","authenticated-orcid":false,"suffix":"III","given":"John A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"885_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijsu.2019.10.015","volume":"72","author":"NB Robinson","year":"2019","unstructured":"Robinson, N. B. et al. The current state of animal models in research: a review. Int. J. Surg. 72, 9\u201313 (2019).","journal-title":"Int. J. Surg."},{"key":"885_CR2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"885_CR3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","volume":"84","author":"I Jubber","year":"2023","unstructured":"Jubber, I. et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur. Urol. 84, 176\u2013190 (2023).","journal-title":"Eur. Urol."},{"key":"885_CR4","first-page":"15","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. 8, 15 (2020).","journal-title":"Med. Sci."},{"key":"885_CR5","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796\u20132810 (2016).","journal-title":"Lancet"},{"key":"885_CR6","doi-asserted-by":"crossref","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne, K. et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front. Oncol. 13, 1170124 (2023).","journal-title":"Front. Oncol."},{"key":"885_CR7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70, 404\u2013423 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"885_CR8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"885_CR9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1535-7163.MCT-12-0508","volume":"12","author":"DJ DeGraff","year":"2013","unstructured":"DeGraff, D. J. et al. Current preclinical models for the advancement of translational bladder cancer research. Mol. Cancer Ther. 12, 121\u2013130 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"885_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrc3858","volume":"15","author":"T Kobayashi","year":"2015","unstructured":"Kobayashi, T., Owczarek, T. B., McKiernan, J. M. & Abate-Shen, C. Modelling bladder cancer in mice: opportunities and challenges. Nat. Rev. Cancer 15, 42\u201354 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"885_CR11","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-02146-5","volume":"17","author":"M Degoricija","year":"2019","unstructured":"Degoricija, M. et al. The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice. J. Transl. Med. 17, 394 (2019).","journal-title":"J. Transl. Med."},{"key":"885_CR12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/01926230290166751","volume":"30","author":"SM Cohen","year":"2002","unstructured":"Cohen, S. M. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol. Pathol. 30, 663\u2013671 (2002).","journal-title":"Toxicol. Pathol."},{"key":"885_CR13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2021.05.010","volume":"154","author":"B Nabavizadeh","year":"2021","unstructured":"Nabavizadeh, B., Amend, G. M. & Breyer, B. N. Workers died of dyes: the discovery of occupational bladder cancers. Urology 154, 4\u20137 (2021).","journal-title":"Urology"},{"key":"885_CR14","first-page":"75","volume":"11","author":"RA Case","year":"1954","unstructured":"Case, R. A., Hosker, M. E., Mc, D. D. & Pearson, J. T. Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br. J. Ind. Med. 11, 75\u2013104 (1954).","journal-title":"Br. J. Ind. Med."},{"key":"885_CR15","first-page":"39","volume":"8","author":"RA Case","year":"1954","unstructured":"Case, R. A. & Hosker, M. E. Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales. Br. J. Prev. Soc. Med. 8, 39\u201350 (1954).","journal-title":"Br. J. Prev. Soc. Med."},{"key":"885_CR16","first-page":"167","volume":"11","author":"JM Barnes","year":"1954","unstructured":"Barnes, J. M. & Magee, P. N. Some toxic properties of dimethylnitrosamine. Br. J. Ind. Med. 11, 167\u2013174 (1954).","journal-title":"Br. J. Ind. Med."},{"key":"885_CR17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bjc.1956.15","volume":"10","author":"PN Magee","year":"1956","unstructured":"Magee, P. N. & Barnes, J. M. The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine. Br. J. Cancer 10, 114\u2013122 (1956).","journal-title":"Br. J. Cancer"},{"key":"885_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00632842","volume":"49","author":"H Druckrey","year":"1962","unstructured":"Druckrey, H., Preussmann, R., Schm\u00e4hl, D. & M\u00fcller, M. Erzeugung von Blasenkrebs an Ratten mit N,N-Dibutylnitrosamin. Naturwissenschaften 49, 19 (1962).","journal-title":"Naturwissenschaften"},{"key":"885_CR19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00524156","volume":"66","author":"H Druckrey","year":"1964","unstructured":"Druckrey, H. et al. Selective induction of bladder cancer in rats by dibutyl- and N-butyl-N-butanol(4)-NITROSAMINE]. Z. Krebsforsch. 66, 280\u2013290 (1964).","journal-title":"Z. Krebsforsch."},{"key":"885_CR20","first-page":"331","volume":"64","author":"G Akagi","year":"1973","unstructured":"Akagi, G., Akagi, A., Kimura, M. & Otsuka, H. Comparison of bladder tumors induced in rats and mice with N-butyl-N-(4-hydroxybutyl)-nitrosoamine. Gan 64, 331\u2013336 (1973).","journal-title":"Gan"},{"key":"885_CR21","first-page":"123","volume":"65","author":"N Ito","year":"1974","unstructured":"Ito, N. et al. Effect of various carcinogenic and non-carcinogenic substances on development of bladder tumors in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosoamine. Gan 65, 123\u2013130 (1974).","journal-title":"Gan"},{"key":"885_CR22","first-page":"367","volume":"17","author":"N Ito","year":"1975","unstructured":"Ito, N. Experimental urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Gann Monogr. Cancer Res. 17, 367\u2013381 (1975).","journal-title":"Gann Monogr. Cancer Res."},{"key":"885_CR23","first-page":"175","volume":"67","author":"M Hirose","year":"1976","unstructured":"Hirose, M. et al. Different susceptibilities of the urinary bladder epithelium of animal species to three nitroso compounds. Gan 67, 175\u2013189 (1976).","journal-title":"Gan"},{"key":"885_CR24","first-page":"401","volume":"60","author":"N Ito","year":"1969","unstructured":"Ito, N., Hiasa, Y., Tamai, A., Okajima, E. & Kitamura, H. Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats. Gan 60, 401\u2013410 (1969).","journal-title":"Gan"},{"key":"885_CR25","first-page":"203","volume":"68","author":"T Shirai","year":"1977","unstructured":"Shirai, T. et al. Early surface changes of the urinary bladder epithelium of different animal species induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine. Gan 68, 203\u2013212 (1977).","journal-title":"Gan"},{"key":"885_CR26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0014-2964(72)90137-5","volume":"8","author":"J Bertram","year":"1972","unstructured":"Bertram, J. & Craig, A. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur. J. Cancer 8, 587\u2013594 (1972).","journal-title":"Eur. J. Cancer"},{"key":"885_CR27","first-page":"81","volume":"67","author":"S Fukushima","year":"1976","unstructured":"Fukushima, S., Hirose, M., Tsuda, H., Shirai, T. & Hirao, K. Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gan 67, 81\u201390 (1976).","journal-title":"Gan"},{"key":"885_CR28","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41388-017-0099-6","volume":"37","author":"D Fantini","year":"2018","unstructured":"Fantini, D. et al. A carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene 37, 1911\u20131925 (2018).","journal-title":"Oncogene"},{"key":"885_CR29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00498257709036241","volume":"7","author":"M Okada","year":"1977","unstructured":"Okada, M. & Ishidate, M. Metabolic fate of N-n-Butyl-N-(4-hydroxybutyl)-nitrosamine and its analogues: selective induction of urinary bladder tumours in the rat. Xenobiotica 7, 11\u201324 (1977).","journal-title":"Xenobiotica"},{"key":"885_CR30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/225021a0","volume":"225","author":"W Lijinsky","year":"1970","unstructured":"Lijinsky, W. & Epstein, S. S. Nitrosamines as environmental carcinogens. Nature 225, 21\u201323 (1970).","journal-title":"Nature"},{"key":"885_CR31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/019262339902700606","volume":"27","author":"K Ogawa","year":"1999","unstructured":"Ogawa, K. et al. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-Butyl-N-(4-Hydroxybutyl)Nitrosamine in rats and mice. Toxicol. Pathol. 27, 645\u2013651 (1999).","journal-title":"Toxicol. Pathol."},{"key":"885_CR32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00390992","volume":"108","author":"N Ito","year":"1984","unstructured":"Ito, N., Shirai, T., Fukushima, S. & Hirose, M. Dose-response study of urinary bladder carcinogenesis in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. J. Cancer Res. Clin. Oncol. 108, 169\u2013173 (1984).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"885_CR33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/bs.mcb.2020.10.020","volume":"163","author":"J Korac-Prlic","year":"2021","unstructured":"Korac-Prlic, J., Degoricija, M., Vilovic, K., Vujevic, S. & Terzic, J. BBN-driven urinary bladder cancer mouse model. Methods Cell Biol. 163, 77\u201392 (2021).","journal-title":"Methods Cell Biol."},{"key":"885_CR34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0165-1218(85)90054-0","volume":"157","author":"CM Moore","year":"1985","unstructured":"Moore, C. M. et al. Mutagenic activation of dialkylnitrosamines by intact urothelial cells. Mutat. Res. 157, 95\u2013105 (1985).","journal-title":"Mutat. Res."},{"key":"885_CR35","first-page":"399","volume":"37","author":"M Nagao","year":"1977","unstructured":"Nagao, M., Suzuki, E., Yasuo, K., Yahagi, T. & Seino, Y. Mutagenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine, a bladder carcinogen, and related compounds. Cancer Res. 37, 399\u2013407 (1977).","journal-title":"Cancer Res."},{"key":"885_CR36","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/carcin\/11.8.1437","volume":"11","author":"L Airoldi","year":"1990","unstructured":"Airoldi, L., Magagnotti, C., Bonfanti, M. & Fanelli, R. Alpha-oxidative metabolism of the bladder carcinogens N-nitrosobutyl(4-hydroxybutyl)amine and N-nitrosobutyl(3-carboxypropyl)amine within the rat isolated bladder. Carcinogenesis 11, 1437\u20131440 (1990).","journal-title":"Carcinogenesis"},{"key":"885_CR37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1349-7006.1988.tb01613.x","volume":"79","author":"J Nakanowatari","year":"1988","unstructured":"Nakanowatari, J., Fukushima, S., Imaida, K., Ito, N. & Nagase, S. Strain differences in N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis in rats. Jpn. J. Cancer Res. 79, 453\u2013459 (1988).","journal-title":"Jpn. J. Cancer Res."},{"key":"885_CR38","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/carcin\/9.11.2109","volume":"9","author":"CC Irving","year":"1988","unstructured":"Irving, C. C. Oxidation of N-butyl-N-(3-formylpropyl)nitrosamine to N-butyl-N-(3-carboxypropyl)nitrosamine in rat liver and inhibition by disulfiram. Carcinogenesis 9, 2109\u20132112 (1988).","journal-title":"Carcinogenesis"},{"key":"885_CR39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0009-2797(92)90113-Y","volume":"82","author":"L Airoldi","year":"1992","unstructured":"Airoldi, L., Magagnotti, C., De Gregorio, G., Moret, M. & Fanelli, R. In vitro metabolism of bladder carcinogenic nitrosamines by rat liver and urothelial cells. Chem. Biol. Interact. 82, 231\u2013240 (1992).","journal-title":"Chem. Biol. Interact."},{"key":"885_CR40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1349-7006.2005.00108.x","volume":"96","author":"T Murai","year":"2005","unstructured":"Murai, T. et al. Differences in susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis between SD\/gShi rats with spontaneous hypospermatogenesis and SD\/cShi rats with spontaneous hydronephrosis. Cancer Sci. 96, 637\u2013644 (2005).","journal-title":"Cancer Sci."},{"key":"885_CR41","first-page":"856","volume":"71","author":"E Suzuki","year":"1980","unstructured":"Suzuki, E. & Okada, M. Metabolic fate of N-butyl-N-(4-hydroxybutyl)nitrosamine in the rat. Gan 71, 856\u2013862 (1980).","journal-title":"Gan"},{"key":"885_CR42","first-page":"3666","volume":"48","author":"M Bonfanti","year":"1988","unstructured":"Bonfanti, M., Magagnotti, C., Bonati, M., Fanelli, R. & Airoldi, L. Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl)amine in rats. Cancer Res. 48, 3666\u20133669 (1988).","journal-title":"Cancer Res."},{"key":"885_CR43","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-04-1906","volume":"64","author":"K Iida","year":"2004","unstructured":"Iida, K. et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 64, 6424\u20136431 (2004).","journal-title":"Cancer Res."},{"key":"885_CR44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/252497a0","volume":"252","author":"Y Hashimoto","year":"1974","unstructured":"Hashimoto, Y. & Kitagawa, H. S. In vitro neoplastic transformation of epithelial cells of rat urinary bladder by nitrosamines. Nature 252, 497\u2013499 (1974).","journal-title":"Nature"},{"key":"885_CR45","first-page":"637","volume":"63","author":"Y Hashimoto","year":"1972","unstructured":"Hashimoto, Y., SUZUKI, E. & OKADA, M. Induction of urinary bladder tumors in Aci\/N rats by butyl (3-carboxypropyl) nitrosoamine, a major urinary metabolite of butyl-(4-hydroxybutyl) nitrosoamine. Gan 63, 637\u2013638_631 (1972).","journal-title":"Gan"},{"key":"885_CR46","first-page":"69","volume":"65","author":"Y Hashimoto","year":"1974","unstructured":"Hashimoto, Y., SUZUKI, K. & OKADA, M. Induction of urinary bladder tumors by intravesicular instillation of butyl (4-hydroxybutyl) nitrosoamine and its principal urinary metabolite, butyl (3-carboxypropyl) nitrosoamine in rats. Gan 65, 69\u201373 (1974).","journal-title":"Gan"},{"key":"885_CR47","first-page":"359","volume":"62","author":"N Ito","year":"1971","unstructured":"Ito, N. et al. Effect of unilateral ureter ligation on development of tumors in the urinary system of rats treated with N-butyl-N-(4-hydroxybutyl) nitrosoamine. Gan 62, 359\u2013365_352 (1971).","journal-title":"Gan"},{"key":"885_CR48","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","volume":"189","author":"DA Green","year":"2013","unstructured":"Green, D. A. et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J. Urol. 189, 1214\u20131221 (2013).","journal-title":"J. Urol."},{"key":"885_CR49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0300-483X(89)90057-7","volume":"59","author":"C Janzowski","year":"1989","unstructured":"Janzowski, C. et al. Investigations on organ-specific metabolism and genotoxic effects of the urinary bladder carcinogen N-nitrosobutyl-3-carboxypropylamine (BCPN) and its analogs N-nitrosodibutylamine (NDBA) and N-nitrosobutyl-4-hydroxybutylamine (4-OH-NDBA). Toxicology 59, 195\u2013209 (1989).","journal-title":"Toxicology"},{"key":"885_CR50","doi-asserted-by":"crossref","first-page":"9073","DOI":"10.1073\/pnas.93.17.9073","volume":"93","author":"JL Jakubczak","year":"1996","unstructured":"Jakubczak, J. L. et al. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc. Natl Acad. Sci. USA 93, 9073\u20139078 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"885_CR51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.mrgentox.2011.11.015","volume":"742","author":"Z He","year":"2012","unstructured":"He, Z., Kosinska, W., Zhao, Z. L., Wu, X. R. & Guttenplan, J. B. Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis. Mutat. Res. 742, 92\u201395 (2012).","journal-title":"Mutat. Res."},{"key":"885_CR52","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1093\/carcin\/bgm146","volume":"28","author":"K Iida","year":"2007","unstructured":"Iida, K. et al. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Carcinogenesis 28, 2398\u20132403 (2007).","journal-title":"Carcinogenesis"},{"key":"885_CR53","doi-asserted-by":"crossref","first-page":"1800427","DOI":"10.1002\/mnfr.201800427","volume":"62","author":"C He","year":"2018","unstructured":"He, C. et al. Sulforaphane normalizes intestinal flora and enhances gut barrier in mice with BBN-induced bladder cancer. Mol. Nutr. Food Res. 62, 1800427 (2018).","journal-title":"Mol. Nutr. Food Res."},{"key":"885_CR54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tifs.2017.02.002","volume":"69","author":"AT Dinkova-Kostova","year":"2017","unstructured":"Dinkova-Kostova, A. T., Fahey, J. W., Kostov, R. V. & Kensler, T. W. KEAP1 and done? Targeting the NRF2 pathway with sulforaphane. Trends Food Sci. Technol. 69, 257\u2013269 (2017).","journal-title":"Trends Food Sci. Technol."},{"key":"885_CR55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0300-483X(88)90202-8","volume":"52","author":"Y Park","year":"1988","unstructured":"Park, Y., Smith, R. D., Combs, A. B. & Kehrer, J. P. Prevention of acetaminophen-induced hepatotoxicity by dimethyl sulfoxide. Toxicology 52, 165\u2013175 (1988).","journal-title":"Toxicology"},{"key":"885_CR56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.immuni.2015.06.011","volume":"43","author":"T Vanden Berghe","year":"2015","unstructured":"Vanden Berghe, T. et al. Passenger mutations confound interpretation of all genetically modified congenic mice. Immunity 43, 200\u2013209 (2015).","journal-title":"Immunity"},{"key":"885_CR57","first-page":"360","volume":"74","author":"E Suzuki","year":"1983","unstructured":"Suzuki, E., Mochizuki, M. & Okada, M. Relationship of urinary N-butyl-N-(3-carboxypropyl) nitrosamine to susceptibility of animals to bladder carcinogenesis by N-butyl-N-(4-hydroxybutyl) nitrosamine. Gan 74, 360\u2013364 (1983).","journal-title":"Gan"},{"key":"885_CR58","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1593\/neo.08432","volume":"10","author":"PD Williams","year":"2008","unstructured":"Williams, P. D., Lee, J. K. & Theodorescu, D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia 10, 838\u2013846, (2008).","journal-title":"Neoplasia"},{"key":"885_CR59","doi-asserted-by":"crossref","first-page":"172","DOI":"10.18632\/oncoscience.439","volume":"5","author":"D Fantini","year":"2018","unstructured":"Fantini, D. & Meeks, J. J. The BBN model: a mouse bladder cancer model featuring basal-subtype gene expression and MLL3\/MLL4 genetic disruption. Oncoscience 5, 172\u2013173 (2018).","journal-title":"Oncoscience"},{"key":"885_CR60","first-page":"60","volume":"74","author":"E Suzuki","year":"1983","unstructured":"Suzuki, E., Anjo, T., Aoki, J. & Okada, M. Species variations in the metabolism of N-butyl-N-(4-hydroxybutyl) nitrosamine and related compounds in relation to urinary bladder carcinogenesis. Gan 74, 60\u201368 (1983).","journal-title":"Gan"},{"key":"885_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2007.12.008","volume":"28","author":"J Rivera","year":"2008","unstructured":"Rivera, J. & Tessarollo, L. Genetic background and the dilemma of translating mouse studies to humans. Immunity 28, 1\u20134 (2008).","journal-title":"Immunity"},{"key":"885_CR62","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/carcin\/21.12.2211","volume":"21","author":"AE Marjou","year":"2000","unstructured":"Marjou, A. E., Delouve\u0301e, A., Thiery, J. P. & Radvanyi, F. Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis 21, 2211\u20132218 (2000).","journal-title":"Carcinogenesis"},{"key":"885_CR63","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1349-7006.2003.tb01400.x","volume":"94","author":"M Mitsuhashi","year":"2003","unstructured":"Mitsuhashi, M. et al. Significance of overexpression of metallothionein in mouse urinary bladder focal lesions induced by treatment with N-butyl-N-(4-hydroxybutyl)-nitrosamine. Cancer Sci. 94, 1052\u20131058 (2003).","journal-title":"Cancer Sci."},{"key":"885_CR64","volume":"7","author":"JA Taylor III","year":"2007","unstructured":"Taylor, J. A. III et al. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer 7, 135 (2007).","journal-title":"BMC Cancer"},{"key":"885_CR65","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<719::AID-IJC18>3.0.CO;2-0","volume":"73","author":"M Yang","year":"1997","unstructured":"Yang, M. et al. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int. J. Cancer 73, 719\u2013724 (1997).","journal-title":"Int. J. Cancer"},{"key":"885_CR66","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jat.1763","volume":"33","author":"MM Oliveira","year":"2013","unstructured":"Oliveira, M. M. et al. Mitochondrial and liver oxidative stress alterations induced by N-butyl-N-(4-hydroxybutyl)nitrosamine: relevance for hepatotoxicity. J. Appl. Toxicol. 33, 434\u2013443 (2013).","journal-title":"J. Appl. Toxicol."},{"key":"885_CR67","first-page":"139","volume":"7","author":"VO Amponsa","year":"2019","unstructured":"Amponsa, V. O. et al. Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274\/Pdl-1 expression. Am. J. Clin. Exp. Urol. 7, 139\u2013152 (2019).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"885_CR68","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s004320050230","volume":"124","author":"S Higashi","year":"1998","unstructured":"Higashi, S. et al. Host genes affecting survival period of chemically induced bladder cancer in mice. J. Cancer Res. Clin. Oncol. 124, 670\u2013676 (1998).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"885_CR69","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1349-7006.1991.tb01808.x","volume":"82","author":"T Murai","year":"1991","unstructured":"Murai, T. et al. Renal pelvic carcinoma which shows metastatic potential to distant organs, induced by N-Butyl-N-(4-hydroxybutyl)nitrosamine in NON\/Shi Mice. Jpn J. Cancer Res. 82, 1371\u20131377 (1991).","journal-title":"Jpn J. Cancer Res."},{"key":"885_CR70","doi-asserted-by":"crossref","first-page":"E3588","DOI":"10.1073\/pnas.1113960109","volume":"109","author":"JB Overdevest","year":"2012","unstructured":"Overdevest, J. B. et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc. Natl Acad. Sci. USA 109, E3588\u2013E3596 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"885_CR71","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76653-7","volume":"10","author":"IB Philyppov","year":"2020","unstructured":"Philyppov, I. B. et al. Alterations in detrusor contractility in rat model of bladder cancer. Sci. Rep. 10, 19651 (2020).","journal-title":"Sci. Rep."},{"key":"885_CR72","doi-asserted-by":"crossref","first-page":"368178","DOI":"10.1155\/2013\/368178","volume":"2013","author":"B Parada","year":"2013","unstructured":"Parada, B. et al. Omega-3 fatty acids inhibit tumor growth in a rat model of bladder cancer. BioMed. Res. Int. 2013, 368178 (2013).","journal-title":"BioMed. Res. Int."},{"key":"885_CR73","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0192623318756004","volume":"46","author":"M Tirmenstein","year":"2018","unstructured":"Tirmenstein, M. et al. Evaluation of uracil, sodium ascorbate, and rosiglitazone as promoters of urinary bladder transitional cell carcinomas in male Sprague-Dawley rats. Toxicol. Pathol. 46, 147\u2013157 (2018).","journal-title":"Toxicol. Pathol."},{"key":"885_CR74","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1349-7006.1988.tb02226.x","volume":"79","author":"M Takahashi","year":"1988","unstructured":"Takahashi, M., Shumiya, S., Maekawa, A., Hayashi, Y. & Nagase, S. High susceptibility of an analbuminemic congenic strain of rats with an F344 genetic background to induced bladder cancer and its possible mechanism. Jpn. J. Cancer Res. 79, 705\u2013709 (1988).","journal-title":"Jpn. J. Cancer Res."},{"key":"885_CR75","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1349-7006.1992.tb02007.x","volume":"83","author":"S Ono","year":"1992","unstructured":"Ono, S., Kurata, Y., Shichino, Y., Sano, M. & Fukushima, S. Synergism of environmental carcinogens and promoters on bladder cancer development initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine in F344 rats. Jpn. J. Cancer Res. 83, 955\u2013963 (1992).","journal-title":"Jpn. J. Cancer Res."},{"key":"885_CR76","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110\u20133115 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"885_CR77","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).","journal-title":"Cancer Cell"},{"key":"885_CR78","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sjodahl","year":"2012","unstructured":"Sjodahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377\u20133386 (2012).","journal-title":"Clin. Cancer Res."},{"key":"885_CR79","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"N Cancer Genome Atlas Research","year":"2014","unstructured":"Cancer Genome Atlas Research, N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322, (2014).","journal-title":"Nature"},{"key":"885_CR80","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.euf.2021.03.017","volume":"8","author":"T van der Kwast","year":"2022","unstructured":"van der Kwast, T. et al. International society of urological pathology expert opinion on grading of urothelial carcinoma. Eur. Urol. Focus. 8, 438\u2013446 (2022).","journal-title":"Eur. Urol. Focus."},{"key":"885_CR81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.01.005","volume":"76","author":"SR Williamson","year":"2010","unstructured":"Williamson, S. R. et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit. Rev. Oncol. Hematol. 76, 112\u2013126 (2010).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"885_CR82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ncb2956","volume":"16","author":"K Shin","year":"2014","unstructured":"Shin, K. et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol. 16, 469\u2013478 (2014).","journal-title":"Nat. Cell Biol."},{"key":"885_CR83","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/his.13063","volume":"70","author":"MR Downes","year":"2017","unstructured":"Downes, M. R. et al. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN 2A deletions in the FGFR 3 pathway. Histopathology 70, 281\u2013289 (2017).","journal-title":"Histopathology"},{"key":"885_CR84","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","volume":"6","author":"N Lobo","year":"2020","unstructured":"Lobo, N. et al. What is the significance of variant histology in urothelial carcinoma? Eur. Urol. Focus. 6, 653\u2013663 (2020).","journal-title":"Eur. Urol. Focus."},{"key":"885_CR85","first-page":"727","volume":"26","author":"C Vasconcelos-N\u00f3brega","year":"2012","unstructured":"Vasconcelos-N\u00f3brega, C., Colaco, A., Lopes, C. & Oliveira, P. BBN as an urothelial carcinogen. Vivo 26, 727\u2013739 (2012).","journal-title":"Vivo"},{"key":"885_CR86","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/carcin\/18.10.1877","volume":"18","author":"S Yamamoto","year":"1997","unstructured":"Yamamoto, S. et al. Genetic instability and p53 mutations in metastatic foci of mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 18, 1877\u20131882 (1997).","journal-title":"Carcinogenesis"},{"key":"885_CR87","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E. & Theodorescu, D. Advances in bladder cancer biology and therapy. Nat. Rev. Cancer 21, 104\u2013121 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"885_CR88","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"885_CR89","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0906549106","volume":"106","author":"KS Chan","year":"2009","unstructured":"Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016\u201314021 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"885_CR90","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","volume":"27","author":"CC Guo","year":"2019","unstructured":"Guo, C. C. et al. Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer. Cell Rep. 27, 1781\u20131793 e1784 (2019).","journal-title":"Cell Rep."},{"key":"885_CR91","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","volume":"11","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat. Rev. Urol. 11, 400\u2013410 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"885_CR92","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania, V. et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 12, 105\u2013117 (2016).","journal-title":"EBioMedicine"},{"key":"885_CR93","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/ncb3038","volume":"16","author":"J Van Batavia","year":"2014","unstructured":"Van Batavia, J. et al. Bladder cancers arise from distinct urothelial sub-populations. Nat. Cell Biol. 16, 982\u2013991 (2014).","journal-title":"Nat. Cell Biol."},{"key":"885_CR94","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/path.6060","volume":"259","author":"J Fontugne","year":"2023","unstructured":"Fontugne, J. et al. Progression-associated molecular changes in basal\/squamous and sarcomatoid bladder carcinogenesis. J. Pathol. 259, 455\u2013467 (2023).","journal-title":"J. Pathol."},{"key":"885_CR95","first-page":"499","volume":"19","author":"DL Lamm","year":"1992","unstructured":"Lamm, D. L. Carcinoma in situ. Urol. Clin. North. Am. 19, 499\u2013508 (1992).","journal-title":"Urol. Clin. North. Am."},{"key":"885_CR96","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","volume":"164","author":"E Solsona","year":"2000","unstructured":"Solsona, E. et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J. Urol. 164, 685\u2013689 (2000).","journal-title":"J. Urol."},{"key":"885_CR97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard, J. et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30, 27\u201342 (2016).","journal-title":"Cancer Cell"},{"key":"885_CR98","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"885_CR99","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks, J. J. et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 17, 259\u2013270 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"885_CR100","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","volume":"39","author":"SA Forbes","year":"2011","unstructured":"Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945\u2013950 (2011).","journal-title":"Nucleic Acids Res."},{"key":"885_CR101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urolonc.2010.04.003","volume":"28","author":"PJ Goebell","year":"2010","unstructured":"Goebell, P. J. & Knowles, M. A. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol. 28, 409\u2013428 (2010).","journal-title":"Urol. Oncol."},{"key":"885_CR102","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/curroncol29030117","volume":"29","author":"IA Voutsadakis","year":"2022","unstructured":"Voutsadakis, I. A. Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies. Curr. Oncol. 29, 1390\u20131407 (2022).","journal-title":"Curr. Oncol."},{"key":"885_CR103","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","volume":"80","author":"J Bellmunt","year":"2020","unstructured":"Bellmunt, J. et al. Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer. Cancer Res. 80, 4476\u20134486 (2020).","journal-title":"Cancer Res."},{"key":"885_CR104","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85902","volume":"1","author":"J Kardos","year":"2016","unstructured":"Kardos, J. et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight 1, e85902 (2016).","journal-title":"JCI Insight"},{"key":"885_CR105","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/carcin\/16.10.2363","volume":"16","author":"S Yamamoto","year":"1995","unstructured":"Yamamoto, S. et al. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON\/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 16, 2363\u20132368 (1995).","journal-title":"Carcinogenesis"},{"key":"885_CR106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/(SICI)1098-2744(199801)21:1<70::AID-MC9>3.0.CO;2-T","volume":"21","author":"K Ogawa","year":"1998","unstructured":"Ogawa, K. et al. Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice. Mol. Carcinog. 21, 70\u201379 (1998).","journal-title":"Mol. Carcinog."},{"key":"885_CR107","first-page":"3806","volume":"58","author":"K Ozaki","year":"1998","unstructured":"Ozaki, K. et al. High susceptibility of p53+\/\u2212 knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res. 58, 3806\u20133811 (1998).","journal-title":"Cancer Res."},{"key":"885_CR108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrurol.2011.193","volume":"9","author":"GJ Netto","year":"2011","unstructured":"Netto, G. J. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat. Rev. Urol. 9, 41\u201351 (2011).","journal-title":"Nat. Rev. Urol."},{"key":"885_CR109","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 977\u2013988 (2019).","journal-title":"Clin. Cancer Res."},{"key":"885_CR110","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/JU.0000000000000351","volume":"203","author":"DS Morera","year":"2020","unstructured":"Morera, D. S. et al. Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: results from multiple cohorts, including TCGA. J. Urol. 203, 62\u201372 (2020).","journal-title":"J. Urol."},{"key":"885_CR111","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/0008-5472.CAN-18-0173","volume":"78","author":"R Saito","year":"2018","unstructured":"Saito, R. et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 78, 3954\u20133968 (2018).","journal-title":"Cancer Res."},{"key":"885_CR112","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41585-022-00591-4","volume":"19","author":"D Theodorescu","year":"2022","unstructured":"Theodorescu, D., Li, Z. & Li, X. Sex differences in bladder cancer: emerging data and call to action. Nat. Rev. Urol. 19, 447\u2013449 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"885_CR113","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ijc.30126","volume":"139","author":"J Ji","year":"2016","unstructured":"Ji, J., Z\u00f6ller, B., Sundquist, J. & Sundquist, K. Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: a national cohort study. Int. J. Cancer 139, 754\u2013758 (2016).","journal-title":"Int. J. Cancer"},{"key":"885_CR114","doi-asserted-by":"crossref","first-page":"eabq2630","DOI":"10.1126\/sciimmunol.abq2630","volume":"7","author":"H Kwon","year":"2022","unstructured":"Kwon, H. et al. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Sci. Immunol. 7, eabq2630 (2022).","journal-title":"Sci. Immunol."},{"key":"885_CR115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.euros.2022.06.007","volume":"43","author":"M Besancon","year":"2022","unstructured":"Besancon, M. et al. Combining antiandrogens with immunotherapy for bladder cancer treatment. Eur. Urol. Open. Sci. 43, 35\u201344 (2022).","journal-title":"Eur. Urol. Open. Sci."},{"key":"885_CR116","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-023-06234-x","volume":"619","author":"HA Abdel-Hafiz","year":"2023","unstructured":"Abdel-Hafiz, H. A. et al. Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature 619, 624\u2013631 (2023).","journal-title":"Nature"},{"key":"885_CR117","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ajpath.2013.01.018","volume":"182","author":"JW Hsu","year":"2013","unstructured":"Hsu, J. W. et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am. J. Pathol. 182, 1811\u20131820 (2013).","journal-title":"Am. J. Pathol."},{"key":"885_CR118","volume":"11","author":"DT Johnson","year":"2016","unstructured":"Johnson, D. T. et al. Conditional expression of the androgen receptor increases susceptibility of bladder cancer in mice. PLoS ONE\u00a011, e0148851 (2016).","journal-title":"PLoS ONE"},{"key":"885_CR119","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13293-016-0115-5","volume":"7","author":"PS Burgoyne","year":"2016","unstructured":"Burgoyne, P. S. & Arnold, A. P. A primer on the use of mouse models for identifying direct sex chromosome effects that cause sex differences in non-gonadal tissues. Biol. Sex. Differ. 7, 68 (2016).","journal-title":"Biol. Sex. Differ."},{"key":"885_CR120","doi-asserted-by":"crossref","first-page":"eaar5598","DOI":"10.1126\/sciadv.aar5598","volume":"4","author":"S Kaneko","year":"2018","unstructured":"Kaneko, S. & Li, X. X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. Sci. Adv. 4, eaar5598 (2018).","journal-title":"Sci. Adv."},{"key":"885_CR121","doi-asserted-by":"crossref","first-page":"107703","DOI":"10.1016\/j.isci.2023.107703","volume":"26","author":"HA Abdel-Hafiz","year":"2023","unstructured":"Abdel-Hafiz, H. A. et al. Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional signatures with prognostic relevance. iScience 26, 107703 (2023).","journal-title":"iScience"},{"key":"885_CR122","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/jnci\/52.3.921","volume":"52","author":"B Giovanella","year":"1974","unstructured":"Giovanella, B., Stehlin, J. & Williams, L. Jr Heterotransplantation of human malignant tumors in \u201cnude\u201d thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. J. Natl Cancer Inst. 52, 921\u2013930 (1974).","journal-title":"J. Natl Cancer Inst."},{"key":"885_CR123","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1006326203858","volume":"17","author":"RM Hoffman","year":"1999","unstructured":"Hoffman, R. M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. N. Drugs 17, 343\u2013360 (1999).","journal-title":"Invest. N. Drugs"},{"key":"885_CR124","volume":"48","author":"GL Dobek","year":"2011","unstructured":"Dobek, G. L. & Godbey, W. T. An orthotopic model of murine bladder cancer. J. Vis. Exp. 48, e2535 (2011).","journal-title":"J. Vis. Exp."},{"key":"885_CR125","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.hoc.2021.02.007","volume":"35","author":"S Zhu","year":"2021","unstructured":"Zhu, S. et al. Preclinical models for bladder cancer research. Hematol. Oncol. Clin. North. Am. 35, 613\u2013632 (2021).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"885_CR126","first-page":"955","volume":"65","author":"JK Cowell","year":"1980","unstructured":"Cowell, J. K. Consistent chromosome abnormalities associated with mouse bladder epithelial cell lines transformed in vitro. J. Natl Cancer Inst. 65, 955\u2013961 (1980).","journal-title":"J. Natl Cancer Inst."},{"key":"885_CR127","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00264623","volume":"16","author":"JE Klaunig","year":"1988","unstructured":"Klaunig, J. E. & Barut, B. A. Role of the implantation site on metastatic ability of the murine MBT-2 transitional cell carcinoma. Urol. Res. 16, 19\u201321 (1988).","journal-title":"Urol. Res."},{"key":"885_CR128","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41596-018-0112-8","volume":"14","author":"G Lorenzatti Hiles","year":"2019","unstructured":"Lorenzatti Hiles, G. et al. A surgical orthotopic approach for studying the invasive progression of human bladder cancer. Nat. Protoc. 14, 738\u2013755 (2019).","journal-title":"Nat. Protoc."},{"key":"885_CR129","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1038\/onc.2017.149","volume":"36","author":"AL Han","year":"2017","unstructured":"Han, A. L. et al. Fibulin-3 promotes muscle-invasive bladder cancer. Oncogene 36, 5243\u20135251 (2017).","journal-title":"Oncogene"},{"key":"885_CR130","volume":"8","author":"W J\u00e4ger","year":"2013","unstructured":"J\u00e4ger, W. et al. Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PLoS ONE\u00a08, e59536 (2013).","journal-title":"PLoS ONE"},{"key":"885_CR131","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ame2.12293","volume":"5","author":"M Bitaraf","year":"2022","unstructured":"Bitaraf, M. et al. Evaluation of direct intramural injection to the bladder wall as a method for developing orthotopic tumor models. Anim. Model. Exp. Med. 5, 575\u2013581 (2022).","journal-title":"Anim. Model. Exp. Med."},{"key":"885_CR132","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/cas.12123","volume":"104","author":"B Park","year":"2013","unstructured":"Park, B. et al. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci. 104, 631\u2013638 (2013).","journal-title":"Cancer Sci."},{"key":"885_CR133","first-page":"1650","volume":"24","author":"A Razzaghdoust","year":"2021","unstructured":"Razzaghdoust, A. et al. Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer. Iran. J. Basic. Med. Sci. 24, 1650\u20131655 (2021).","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"885_CR134","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/BLC-200281","volume":"6","author":"YSR Kita","year":"2020","unstructured":"Kita, Y. S., R. Inoue, T. Kim, W. Ogawa, O. Kobayashi, T. Patient-derived urothelial cancer xenograft models: a systematic review and future perspectives. Bladder Cancer 6, 131-141 (2020).","journal-title":"Bladder Cancer"},{"key":"885_CR135","doi-asserted-by":"crossref","first-page":"32718","DOI":"10.18632\/oncotarget.26024","volume":"9","author":"J Gills","year":"2018","unstructured":"Gills, J. et al. A patient-derived orthotopic xenograft model enabling human high-grade urothelial cell carcinoma of the bladder tumor implantation, growth, angiogenesis, and metastasis. Oncotarget 9, 32718\u201332729 (2018).","journal-title":"Oncotarget"},{"key":"885_CR136","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.humpath.2014.09.007","volume":"46","author":"W Tian","year":"2015","unstructured":"Tian, W. et al. Utility of uroplakin II expression as a marker of urothelial carcinoma. Hum. Pathol. 46, 58\u201364 (2015).","journal-title":"Hum. Pathol."},{"key":"885_CR137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/ilar\/ilw001","volume":"57","author":"AL Hudson","year":"2016","unstructured":"Hudson, A. L. & Colvin, E. K. Transgenic mouse models of SV40-induced cancer. ILAR J. 57, 44\u201354 (2016).","journal-title":"ILAR J."},{"key":"885_CR138","first-page":"3512","volume":"59","author":"ZT Zhang","year":"1999","unstructured":"Zhang, Z. T., Pak, J., Shapiro, E., Sun, T. T. & Wu, X. R. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 59, 3512\u20133517 (1999).","journal-title":"Cancer Res."},{"key":"885_CR139","doi-asserted-by":"crossref","first-page":"9413","DOI":"10.1158\/0008-5472.CAN-09-2158","volume":"69","author":"F He","year":"2009","unstructured":"He, F. et al. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res. 69, 9413\u20139421 (2009).","journal-title":"Cancer Res."},{"key":"885_CR140","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","volume":"23","author":"AM Puzio-Kuter","year":"2009","unstructured":"Puzio-Kuter, A. M. et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes. Dev. 23, 675\u2013680 (2009).","journal-title":"Genes. Dev."},{"key":"885_CR141","doi-asserted-by":"crossref","first-page":"215924","DOI":"10.1016\/j.canlet.2022.215924","volume":"550","author":"F He","year":"2022","unstructured":"He, F., Zhang, F., Liao, Y., Tang, M.-S. & Wu, X.-R. Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal\/squamous-subtype muscle-invasive bladder cancer. Cancer Lett. 550, 215924 (2022).","journal-title":"Cancer Lett."},{"key":"885_CR142","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3678","volume":"20","author":"T Rampias","year":"2014","unstructured":"Rampias, T. et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat. Med. 20, 1199\u20131205 (2014).","journal-title":"Nat. Med."},{"key":"885_CR143","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41585-018-0005-1","volume":"15","author":"A Goriki","year":"2018","unstructured":"Goriki, A. et al. Unravelling disparate roles of Notch in bladder cancer. Nat. Rev. Urol. 15, 345\u2013357 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"885_CR144","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-15-2360","volume":"22","author":"T Hayashi","year":"2016","unstructured":"Hayashi, T. et al. Not all Notch is created equal: the oncogenic role of Notch2 in bladder cancer and its implications for targeted therapy. Clin. Cancer Res. 22, 2981\u20132992 (2016).","journal-title":"Clin. Cancer Res."},{"key":"885_CR145","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1172\/JCI78185","volume":"125","author":"A Maraver","year":"2015","unstructured":"Maraver, A. et al. NOTCH pathway inactivation promotes bladder cancer progression. J. Clin. Invest. 125, 824\u2013830 (2015).","journal-title":"J. Clin. Invest."},{"key":"885_CR146","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","volume":"408","author":"B Vogelstein","year":"2000","unstructured":"Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307\u2013310 (2000).","journal-title":"Nature"},{"key":"885_CR147","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-19-2230","volume":"26","author":"K Kobatake","year":"2020","unstructured":"Kobatake, K. et al. Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction. Clin. Cancer Res. 26, 2065\u20132079 (2020).","journal-title":"Clin. Cancer Res."},{"key":"885_CR148","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/carcin\/bgy139","volume":"40","author":"JL Sottnik","year":"2019","unstructured":"Sottnik, J. L. et al. Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice. Carcinogenesis 40, 194\u2013201 (2019).","journal-title":"Carcinogenesis"},{"key":"885_CR149","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3390\/cancers15061654","volume":"15","author":"BL Woolbright","year":"2023","unstructured":"Woolbright, B. L. et al. Pyruvate dehydrogenase kinase 4 deficiency increases tumorigenesis in a murine model of bladder cancer. Cancers 15, 1654 (2023).","journal-title":"Cancers"},{"key":"885_CR150","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169241","volume":"134","author":"A Okato","year":"2024","unstructured":"Okato, A. et al. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J. Clin. Invest. 134, e169241 (2024).","journal-title":"J. Clin. Invest."},{"key":"885_CR151","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26421-6","volume":"12","author":"T Tate","year":"2021","unstructured":"Tate, T. et al. Pparg signaling controls bladder cancer subtype and immune exclusion. Nat. Commun. 12, 6160 (2021).","journal-title":"Nat. Commun."},{"key":"885_CR152","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"885_CR153","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/1078-0432.CCR-20-4419","volume":"27","author":"S Koutros","year":"2021","unstructured":"Koutros, S. et al. Targeted deep sequencing of bladder tumors reveals novel associations between cancer gene mutations and mutational signatures with major risk factors. Clin. Cancer Res. 27, 3725\u20133733 (2021).","journal-title":"Clin. Cancer Res."},{"key":"885_CR154","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3390\/ijms21176072","volume":"21","author":"T Hayashi","year":"2020","unstructured":"Hayashi, T. et al. Mutational landscape and environmental effects in bladder cancer. Int. J. Mol. Sci. 21, 6072 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"885_CR155","doi-asserted-by":"crossref","first-page":"9095","DOI":"10.1007\/s13277-015-3973-2","volume":"36","author":"AI Faustino-Rocha","year":"2015","unstructured":"Faustino-Rocha, A. I., Ferreira, R., Oliveira, P. A., Gama, A. & Ginja, M. N-Methyl-N-nitrosourea as a mammary carcinogenic agent. Tumour Biol. 36, 9095\u20139117 (2015).","journal-title":"Tumour Biol."},{"key":"885_CR156","first-page":"6668","volume":"50","author":"GD Steinberg","year":"1990","unstructured":"Steinberg, G. D., Brendler, C. B., Ichikawa, T., Squire, R. A. & Isaacs, J. T. Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res. 50, 6668\u20136674 (1990).","journal-title":"Cancer Res."},{"key":"885_CR157","first-page":"980","volume":"14","author":"ACC Salustiano","year":"2021","unstructured":"Salustiano, A. C. C. et al. Autochthonous male urothelial carcinoma immune competent model: from induction to BCG transurethral treatment. Int. J. Clin. Exp. Pathol. 14, 980\u2013986 (2021).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"885_CR158","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","volume":"5","author":"M Kates","year":"2017","unstructured":"Kates, M. et al. Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol. Res. 5, 594\u2013603 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"885_CR159","doi-asserted-by":"crossref","first-page":"160.e123","DOI":"10.1016\/j.urolonc.2017.11.024","volume":"36","author":"T Yoshida","year":"2018","unstructured":"Yoshida, T. et al. Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: development of organoids and an immortalized cell line. Urol. Oncol. 36, 160.e123\u2013160.e132 (2018).","journal-title":"Urol. Oncol."},{"key":"885_CR160","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI112055","volume":"76","author":"LA Spry","year":"1985","unstructured":"Spry, L. A., Zenser, T. V., Cohen, S. M. & Davis, B. B. Role of renal metabolism and excretion in 5-nitrofuran-induced uroepithelial cancer in the rat. J. Clin. Invest. 76, 1025\u20131031 (1985).","journal-title":"J. Clin. Invest."},{"key":"885_CR161","first-page":"1998","volume":"27","author":"E Ert\u00fcrk","year":"1967","unstructured":"Ert\u00fcrk, E. et al. The production of carcinoma of the urinary bladder in rats by feeding N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide1.Cancer Res. 27, 1998\u20132002 (1967).","journal-title":"Cancer Res."},{"key":"885_CR162","first-page":"1309","volume":"30","author":"E Ert\u00fcrk","year":"1970","unstructured":"Ert\u00fcrk, E., Cohen, S. M. & Bryan, G. T. Urinary bladder carcinogenicity of N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide in female Swiss mice. Cancer Res. 30, 1309\u20131311 (1970).","journal-title":"Cancer Res."},{"key":"885_CR163","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24\u201337 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"885_CR164","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","volume":"9","author":"M Joseph","year":"2019","unstructured":"Joseph, M. & Enting, D. Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications. Front. Oncol. 9, 1270 (2019).","journal-title":"Front. Oncol."},{"key":"885_CR165","doi-asserted-by":"crossref","first-page":"E672","DOI":"10.1073\/pnas.1313580111","volume":"111","author":"CD Morrison","year":"2014","unstructured":"Morrison, C. D. et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc. Natl Acad. Sci. USA 111, E672\u2013E681 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"885_CR166","doi-asserted-by":"crossref","first-page":"1120329","DOI":"10.3389\/fonc.2023.1120329","volume":"13","author":"SD Shah","year":"2023","unstructured":"Shah, S. D. et al. Syngeneic model of carcinogen-induced tumor mimics basal\/squamous, stromal-rich, and neuroendocrine molecular and immunological features of muscle-invasive bladder cancer. Front. Oncol. 13, 1120329 (2023).","journal-title":"Front. Oncol."},{"key":"885_CR167","doi-asserted-by":"crossref","first-page":"eabc4552","DOI":"10.1126\/science.abc4552","volume":"371","author":"GD Sepich-Poore","year":"2021","unstructured":"Sepich-Poore, G. D. et al. The microbiome and human cancer. Science 371, eabc4552 (2021).","journal-title":"Science"},{"key":"885_CR168","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41585-022-00611-3","volume":"19","author":"A Martin","year":"2022","unstructured":"Martin, A., Woolbright, B. L., Umar, S., Ingersoll, M. A. & Taylor, J. A. III Bladder cancer, inflammageing and microbiomes. Nat. Rev. Urol. 19, 495\u2013509 (2022).","journal-title":"Nat. Rev. Urol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00885-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00885-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00885-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T09:06:19Z","timestamp":1732871179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00885-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":168,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00885-9","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"10 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}